Novavax, Inc.

NASDAQ:NVAX   3:59:55 PM EDT
193.40
-9.84 (-4.84%)
4:35:24 PM EDT: $193.00 -0.40 (-0.21%)
Products, Regulatory

Novavax Publishes Results Of UK Phase 3 Clinical Trial, Showing High Levels Of Efficacy Of COVID-19 Vaccine

Published: 06/30/2021 21:52 GMT
Novavax, Inc. (NVAX) - Novavax Publishes Results of United Kingdom Phase 3 Clinical Trial in New England Journal of Medicine, Demonstrating High Levels of Efficacy of Covid-19 Vaccine.
Novavax Inc - Publication of Final Analysis Highlights Robust Safety and Efficacy Data of Nvx-cov2373 in Large, Pivotal Placebo-controlled Trial.
Novavax - Final Analysis Confirmed Overall Efficacy of 89.7% With Over 60% of Cases Caused by B.
1.1.
7 (alpha) Variant.
Novavax Inc - Final Analysis Confirmed Overall Efficacy of 96.4% Against Non-b.
1.1.
7 (non-alpha) Variants.